The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: A pilot study

N. F. Kalkers; F. Barkhof; E. Bergers; R. van Schijndel; C. H. Polman

doi:https://doi.org/10.1191/1352458502ms849xx

The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: A pilot study

N. F. Kalkers, F. Barkhof, E. Bergers, R. van Schijndel, C. H. Polman

VU University medical center

Research output: Contribution to journal › Article › Academic › peer-review

129 Citations (Scopus)

Abstract

Progressive axonal loss is the most likely pathologic correlate of irreversible neurologic impairment in primary progressive multiple sclerosis. In a run-in versus treatment trial, we show that the neuroprotective agent riluzole seems to reduce the rate of cervical cord atrophy and the development of hypointense T1 brain lesions on magnetic resonance imaging.

Original language	English
Pages (from-to)	532-533
Journal	MULTIPLE SCLEROSIS
Volume	8
Issue number	6
DOIs	https://doi.org/10.1191/1352458502ms849xx
Publication status	Published - 2002

Access to Document

https://doi.org/10.1191/1352458502ms849xx

Cite this

@article{7181b33adbc649e6b374c037b9131ca2,

title = "The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: A pilot study",

abstract = "Progressive axonal loss is the most likely pathologic correlate of irreversible neurologic impairment in primary progressive multiple sclerosis. In a run-in versus treatment trial, we show that the neuroprotective agent riluzole seems to reduce the rate of cervical cord atrophy and the development of hypointense T1 brain lesions on magnetic resonance imaging.",

author = "Kalkers, {N. F.} and F. Barkhof and E. Bergers and {van Schijndel}, R. and Polman, {C. H.}",

year = "2002",

doi = "https://doi.org/10.1191/1352458502ms849xx",

language = "English",

volume = "8",

pages = "532--533",

journal = "MULTIPLE SCLEROSIS",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "6",

}

TY - JOUR

T1 - The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: A pilot study

AU - Kalkers, N. F.

AU - Barkhof, F.

AU - Bergers, E.

AU - van Schijndel, R.

AU - Polman, C. H.

PY - 2002

Y1 - 2002

N2 - Progressive axonal loss is the most likely pathologic correlate of irreversible neurologic impairment in primary progressive multiple sclerosis. In a run-in versus treatment trial, we show that the neuroprotective agent riluzole seems to reduce the rate of cervical cord atrophy and the development of hypointense T1 brain lesions on magnetic resonance imaging.

AB - Progressive axonal loss is the most likely pathologic correlate of irreversible neurologic impairment in primary progressive multiple sclerosis. In a run-in versus treatment trial, we show that the neuroprotective agent riluzole seems to reduce the rate of cervical cord atrophy and the development of hypointense T1 brain lesions on magnetic resonance imaging.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=1842845857&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/12474997

U2 - https://doi.org/10.1191/1352458502ms849xx

DO - https://doi.org/10.1191/1352458502ms849xx

M3 - Article

C2 - 12474997

SN - 1352-4585

VL - 8

SP - 532

EP - 533

JO - MULTIPLE SCLEROSIS

JF - MULTIPLE SCLEROSIS

IS - 6

ER -

The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: A pilot study

Abstract

Access to Document

Other files and links

Cite this